Treatment strategies and pharmacist‐led medication management for Helicobacter pylori infection

Abstract

Half of the world's population is Helicobacter pylori carrier. Updated guidelines and consensus have been issued across regions with the main aim of reducing social transmission and increasing H. pylori eradication rate. Although alternative therapies including traditional Chinese medicine and probiotics have also been used to improve H. pylori eradication rate in clinical practice, current mainstream treatment is still dependent on triple and quadruple therapies that includes antibacterial agents (e.g., amoxicillin and furazolidone) and proton pump inhibitor. Researches also assessed the eradication rate of optimized high-dose dual therapy in treating H. pylori infection. With the increase of antibiotic resistance rate, the treatment strategies for H. pylori infection are constantly adjusted and improved. Besides, low medication compliance is another key influencing factor for H. pylori treatment failure. Emerging studies indicate that pharmacists' intervention and new pharmaceutical care methods can enhance patient medication compliance, reduce adverse drug reactions, and improve H. pylori eradication rate. The purpose of this review is to summarize the advances in treating H. pylori infection and highlight the necessity of developing novel strategies to cope with the increasing challenges and to achieve personalized medication. Also, this review attaches great importance to pharmacists in optimizing H. pylori treatment outcomes as a routine part of therapy.

Function of proprotein convertase subtilisin/kexin type 9 and its role in central nervous system diseases: An update on clinical evidence

“…Clinical pharmacists should attach great importance to the postmarketing evaluation of PCSK9 inhibitors, due to their advantages of medication management as reported (Wang et al, 2023). Third, because PCSK9 inhibitors have been in the market for such a short time, their combination with drugs for the treatment of CNS diseases may contribute to the progress of CNS diseases, which has to be investigated in the future clinical study design.…”

“…Second, monitoring the neurological effects during clinical use of PCSK9 inhibitors through the adverse drug reaction system and evaluating its causal relationship is of importance to reveal the safety of PCSK9 inhibitors. Clinical pharmacists should attach great importance to the postmarketing evaluation of PCSK9 inhibitors, due to their advantages of medication management as reported (Wang et al, 2023).…”